Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc.
Your view on CMRA
Overview
What the company does, where it operates, and who runs it.
About Comera Life Sciences Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael G. Campbell
- Headquarters
- 12 Gill Street, Woburn, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael G. Campbell
- Headquarters
- 12 Gill Street, Woburn, MA, US
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Comera Life Sciences Holdings, Inc., and the rating behind it. CMRA last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Comera Life Sciences Holdings, Inc.. Starting points for Comera Life Sciences Holdings, Inc.: EPS -$1.72, beta -20.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Comera Life Sciences Holdings, Inc.. Comera Life Sciences Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Comera Life Sciences Holdings, Inc.. Trailing twelve-month EPS for Comera Life Sciences Holdings, Inc. stands at -$1.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Comera Life Sciences Holdings, Inc.. Comera Life Sciences Holdings, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Comera Life Sciences Holdings, Inc. valued side by side against its closest peers. Comera Life Sciences Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Comera Life Sciences Holdings, Inc., and how their positions are changing. At a $3,074 market value, institutional positions materially move Comera Life Sciences Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Comera Life Sciences Holdings, Inc. executives and directors. Shares of Comera Life Sciences Holdings, Inc. have traded between $0.0001 and $0.0002 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Comera Life Sciences Holdings, Inc.. Comera Life Sciences Holdings, Inc. is a $3,074 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Comera Life Sciences Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Comera Life Sciences Holdings, Inc.. Coverage tracks Comera Life Sciences Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.